BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 27169477)

  • 21. Hydroa vacciniforme-like lymphoproliferative disorder: Clinicopathologic study of 41 cases.
    Liu Y; Ma C; Wang G; Wang L
    J Am Acad Dermatol; 2019 Aug; 81(2):534-540. PubMed ID: 30654082
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantification of Epstein-Barr virus DNA is helpful for evaluation of chronic active Epstein-Barr virus infection.
    Sakamoto Y; Mariya Y; Kubo K
    Tohoku J Exp Med; 2012 Aug; 227(4):307-11. PubMed ID: 22850617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epstein-Barr virus involvement in the pathogenesis of hydroa vacciniforme: an assessment of seven adult patients with long-term follow-up.
    Verneuil L; Gouarin S; Comoz F; Agbalika F; Creveuil C; Varna M; Vabret A; Janin A; Leroy D
    Br J Dermatol; 2010 Jul; 163(1):174-82. PubMed ID: 20367637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of Epstein-Barr virus (EBV) BZLF1 gene promoter variants and comparison of cellular gene expression profiles in Japanese patients with infectious mononucleosis, chronic active EBV infection, and EBV-associated hemophagocytic lymphohistiocytosis.
    Imajoh M; Hashida Y; Murakami M; Maeda A; Sato T; Fujieda M; Wakiguchi H; Daibata M
    J Med Virol; 2012 Jun; 84(6):940-6. PubMed ID: 22511310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary cutaneous Epstein-Barr virus-associated T-cell lymphoproliferative disorder-2 cases with unusual, prolonged clinical course.
    Park S; Lee DY; Kim WS; Ko YH
    Am J Dermatopathol; 2010 Dec; 32(8):832-6. PubMed ID: 20595887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The association of latent Epstein-Barr virus infection with hydroa vacciniforme.
    Iwatsuki K; Xu Z; Takata M; Iguchi M; Ohtsuka M; Akiba H; Mitsuhashi Y; Takenoshita H; Sugiuchi R; Tagami H; Kaneko F
    Br J Dermatol; 1999 Apr; 140(4):715-21. PubMed ID: 10233328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of skin blister fluids from children with Epstein-Barr virus-associated lymphoproliferative disease.
    Wada T; Toma T; Miyazawa H; Koizumi E; Shirahashi T; Matsuda Y; Yachie A
    J Dermatol; 2018 Apr; 45(4):444-449. PubMed ID: 29352500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival rates and prognostic factors of Epstein-Barr virus-associated hydroa vacciniforme and hypersensitivity to mosquito bites.
    Miyake T; Yamamoto T; Hirai Y; Otsuka M; Hamada T; Tsuji K; Morizane S; Suzuki D; Aoyama Y; Iwatsuki K
    Br J Dermatol; 2015 Jan; 172(1):56-63. PubMed ID: 25234411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical and pathological features of 13 children with Epstein-Barr virus-positive lymphoproliferative disease].
    Chen TM; Deng ZJ; Hu B; Hu HL; Chen HY; Li SY; Liu G
    Zhonghua Er Ke Za Zhi; 2018 Oct; 56(10):759-764. PubMed ID: 30293280
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparative Study of the Clinical Pathology, Immunophenotype, Epstein-Barr Virus Infection Status, and Gene Rearrangements in Adult and Child Patients With Hydroa Vacciniforme-Like Lymphoproliferative Disorder.
    Wen PF; Zhang M; Wang TT; Liu HJ; Zhang WY; Liu WP; Wang L
    Am J Dermatopathol; 2019 Jan; 41(1):7-15. PubMed ID: 30085959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EBV-associated hydroa vacciniforme-like T-cell lymphoma.
    Roy SF; Ghazawi FM; Powell J; Kokta V; Bélisle A
    Br J Haematol; 2019 Sep; 186(6):802. PubMed ID: 31218678
    [No Abstract]   [Full Text] [Related]  

  • 32. Epstein-Barr virus-associated T/natural killer-cell lymphomas in the elderly: the first consensus meeting in Kofu 2013.
    Hamada T; Nakamura S; Ko YH; Yoshino T; Ohshima K; Matsuzawa T; Miura K; Takahashi T; Nomura H; Hoshino T; Suzuki D; Shimada S; Iwatsuki K
    J Dermatol; 2014 Jan; 41(1):40-2. PubMed ID: 24438143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of virus infected-T cell in severe hepatitis caused by primary Epstein-Barr virus infection.
    Hara S; Hoshino Y; Naitou T; Nagano K; Iwai M; Suzuki K; Yamamoto K; Nagasaka T; Morishima T; Kimura H
    J Clin Virol; 2006 Mar; 35(3):250-6. PubMed ID: 16181807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic and disease severity determination criteria for hydroa vacciniforme lymphoproliferative disorders and severe mosquito bite allergy.
    Hirai Y; Asada H; Hamada T; Kawada JI; Kimura H; Arai A; Ohshima K; Ohga S; Iwatsuki K;
    J Dermatol; 2023 Jul; 50(7):e198-e205. PubMed ID: 37249004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disorders.
    Park S; Ko YH
    J Dermatol; 2014 Jan; 41(1):29-39. PubMed ID: 24438142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of Epstein-Barr virus (EBV)-positive NK cells isolated from hydroa vacciniforme-like eruptions.
    Demachi A; Nagata H; Morio T; Oyoshi MK; Zhang Y; Tabata N; Kimura N; Shimizu N; Yamamoto K
    Microbiol Immunol; 2003; 47(7):543-52. PubMed ID: 12953848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cutaneous lymphoproliferative disorders associated with Epstein-Barr virus infection: a clinical overview.
    Iwatsuki K; Xu Z; Ohtsuka M; Kaneko F
    J Dermatol Sci; 2000 Apr; 22(3):181-95. PubMed ID: 10698155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current research on chronic active Epstein-Barr virus infection in Japan.
    Fujiwara S; Kimura H; Imadome K; Arai A; Kodama E; Morio T; Shimizu N; Wakiguchi H
    Pediatr Int; 2014 Apr; 56(2):159-66. PubMed ID: 24528553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A Case of Severe Chronic Active Epstein-Barr Virus Infection with Aplastic Anemia and Hepatitis].
    Lee JI; Lee SW; Han NI; Ro SM; Noh YS; Jang JW; Bae SH; Choi JY; Yoon SK
    Korean J Gastroenterol; 2016 Jan; 67(1):39-43. PubMed ID: 26809631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hydroa vacciniforme-like lymphoma: a chronic EBV+ lymphoproliferative disorder with risk to develop a systemic lymphoma.
    Quintanilla-Martinez L; Ridaura C; Nagl F; Sáez-de-Ocariz M; Durán-McKinster C; Ruiz-Maldonado R; Alderete G; Grube P; Lome-Maldonado C; Bonzheim I; Fend F
    Blood; 2013 Oct; 122(18):3101-10. PubMed ID: 23982171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.